Importance of the field: Mesenchymal stem cells (MSCs) have the greatest potential for use
in cell-based therapy of human heart diseases, especially in myocardial infarcts. The …

Despite advances in clinical management, cardiovascular disease remains the leading
cause of death in America. While cardiomyocytes retain limited plasticity following …

Possible cardiac repair by adult stem cell transplantation is currently hampered by poor cell
viability and delivery efficiency, uncertain differentiating fate in vivo, the needs of ex vivo cell …

Mesenchymal stem cells (MSCs) may improve myocardial function after I/R injury via
paracrine effects, including the release of growth factors. Genetic modification of MSCs is an …

Background Bone marrow-derived mesenchymal stem cells (MSC) improve myocardial
recovery after ischemia/reperfusion (I/R) injury. These effects are mediated in part by the …

Toll-like receptor 2 (TLR2), a key component of the innate immune system, is linked to
inflammation and myocardial dysfunction after ischemia-reperfusion injury (I/R). Treatment of …

Aims Cardiac progenitor cells (CPCs) have been shown to promote cardiac regeneration in
vivo. Understanding the function of CPCs is essential for further implementation of these …

Bone marrow has been proposed as a potential source of stem cells for regenerative
medicine. In the eye, degeneration of neural cells in the retina is a hallmark of such …

Mesenchymal stem cell (MSC) infusion may reduce myocardial ischemic injury. TNF-α is a
proinflammatory cytokine produced in large quantities during myocardial ischemia that can …

Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are
known to have the potential for cardiotoxicity and should be used with caution in patients …